Angiotensin I

The European Commission has granted marketing authorisation for Lokelma ( formerly ZS-9, sodium Zirconium cyclosilicate ) for the treatment of...


The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac...


The quality of evidence regarding patient-centered outcomes in adults with heart failure after Sacubitril combined with Valsartan ( Entresto )...


European Society of Cardiology ( ESC ) Guidelines for the diagnosis and treatment of acute and chronic heart failure are...


The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury...


New data showed Empagliflozin ( Jardiance ) reduces the risk for new-onset or worsening kidney disease by 39% versus placebo...


In the prospective, open-label, non-interventional, multicenter RESPONSIfVE study, the effectiveness, response rates and tolerability of Ivabradine ( Corlentor, Procoralan )...


A study assessed whether the benefit of Sacubitril / Valsartan ( Entresto ) therapy varied with clinical stability. Despite the benefit...


Angioedema induced by treatment with angiotensin-converting-enzyme ( ACE ) inhibitors accounts for one third of angioedema cases in the emergency...


Hypertension is a common diabetes comorbidity that affects the majority of patients, with the prevalence depending on type of diabetes,...


A study sought to hypothesize that elevated B-type natriuretic peptide ( BNP ) could act as an endogenous neprilysin inhibitor. A...


The angiotensin-receptor-neprilysin inhibitor ( ARNI ) Valsartan / Sacubitril ( Entresto; LCZ696 ) reduced cardiovascular deaths and all-cause mortality compared...


A study has tested the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart...


The FDA ( Food and Drug Administration ) has approved Veltassa ( Patiromer for oral suspension ) to treat hyperkalemia,...


Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors...


Entresto ( Sacubitril / Valsartan ), previously known as LCZ696 has been approved by Health Canada for the treatment of...


A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF...


The European Commission ( EC ) has approved Entresto ( Sacubitril / Valsartan ) for the treatment of adult patients...


A 8-week, multicenter, open-label study has assessed the safety and efficacy of LCZ696 ( Entresto ), a first-in-class angiotensin receptor...


The effect of LCZ696 on blood pressure was evaluated in patients with heart failure with preserved ejection fraction ( HFpEF...